Bod Australia (ASX:BOD) - CEO, Jo Patterson
CEO, Jo Patterson
Source: Wise Owl
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Bod Australia (BOD) sees positive results from its study into the safety and efficacy of a cannabigerol (CBG) dominant cannabis extract
  • The study is part of the basis for the launch of a new medical cannabis product that will be sold under the company’s existing medicinal cannabis brand, MediCabilis CBG 50
  • The new product is expected to launch next month
  • CBG has shown to be beneficial in the treatment of fibromyalgia, inflammatory bowel disease and irritable bowel syndrome (IBS) amongst others
  • BOD shares are in the grey and trading at 14 cents per share at 1:00 pm AEST

Bod Australia (BOD) has seen positive results from its study into the safety and efficacy of a cannabigerol (CBG) dominant cannabis extract.

The study is part of the basis for the launch of a new medical cannabis product that will be sold under the company’s existing medicinal cannabis brand, MediCabilis CBG 50. The new product is expected to launch next month.

CBG is a non-intoxicating cannabinoid compound found in the cannabis plant. The extract has shown to be beneficial in the treatment of fibromyalgia, inflammatory bowel disease and irritable bowel syndrome (IBS) amongst others.

The study was completed over three months to assess the safety and efficacy of the drug in patients suffering from symptoms associated with fibromyalgia, inflammatory bowel disease and anxiety.

In the trial, 74 per cent of participants noticed improvements to their condition within two to four weeks of using MediCabilis CBG 50.

Trial data will be shared with doctors and approved prescribers in both Australia and the UK to help in the ongoing educational initiative undertaken by the company.

“The completion of this initiative has highlighted that MediCabilis CBG 50 is both safe
and effective for use across a range of new symptoms that our product has not been previously prescribed for,” CEO Jo Patterson said.

“The study will also allow Bod to explore the possibility of using its extract as an alternative treatment or all encompassing route for conditions that require a mix of surgery, medication and other routines.”

On the market this afternoon, BOD shares were in the grey and trading at 14 cents per share at 1:00 pm AEST.

bod by the numbers
More From The Market Online

Market Close: ASX slides 1.58% as global AI sell-off rattles investors

My nerves, along with my portfolio, have taken a beating over the last couple of weeks – and I’m sick of seeing red!

Market Close: Materials drag ASX lower as seven sectors finish higher

The Australian share market finished lower on Monday, with weakness across the resources sector weighing on the broader market despite gains across most

Market Close: ASX slides as resources and miners lead broad market sell-off

The Australian sharemarket came under renewed pressure on Tuesday 17th Nov, with selling extending across almost every sector as resources and energy

Market Close: ASX slides as technology and materials stocks lead broad market decline

The Australian share market finished lower on Wednesday, with the S&P/ASX 200 falling 0.69% to close at 8,821.80 points.